<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="/wp-content/plugins/xml-sitemap-feed/assets/sitemap-news.xsl?ver=5.7.7"?>
<!-- generated-on="2026-10-29T09:20:57+00:00" -->
<!-- generator="XML Sitemap & Google News for WordPress" -->
<!-- generator-url="https://status301.net/wordpress-plugins/xml-sitemap-feed/" -->
<!-- generator-version="5.7.7" -->
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9" >
<url><loc>https://www.medicinanews.it/cancro-endometriale-avanzato-trattamento-adc/369028/</loc><news:news><news:publication><news:name>Medicinanews.it</news:name><news:language>it</news:language></news:publication><news:publication_date>2026-10-29T10:18:24+01:00</news:publication_date><news:title>Il farmaco ADC di Merck e Kelun-Biotech riduce la mortalità nel cancro endometriale avanzato</news:title></news:news></url>
<url><loc>https://www.medicinanews.it/oppioidi-mal-di-schiena-dipendenza-studio/369025/</loc><news:news><news:publication><news:name>Medicinanews.it</news:name><news:language>it</news:language></news:publication><news:publication_date>2026-10-29T09:44:09+01:00</news:publication_date><news:title>Oppioidi nel mal di schiena cronico: lo studio che conferma i rischi di dipendenza</news:title></news:news></url>
<url><loc>https://www.medicinanews.it/pbm-audit-farmacie-indipendenti-indagine/369022/</loc><news:news><news:publication><news:name>Medicinanews.it</news:name><news:language>it</news:language></news:publication><news:publication_date>2026-10-29T08:59:14+01:00</news:publication_date><news:title>Le farmacie indipendenti nella morsa degli audit dei PBM: quando i controlli diventano punizione</news:title></news:news></url>
<url><loc>https://www.medicinanews.it/terapie-geniche-personalizzate-malattie-rare-fda/369019/</loc><news:news><news:publication><news:name>Medicinanews.it</news:name><news:language>it</news:language></news:publication><news:publication_date>2026-10-29T08:55:14+01:00</news:publication_date><news:title>FDA accelera l&#8217;approvazione delle terapie geniche personalizzate per le malattie rare</news:title></news:news></url>
<url><loc>https://www.medicinanews.it/idrosadenite-suppurativa-linee-guida/369016/</loc><news:news><news:publication><news:name>Medicinanews.it</news:name><news:language>it</news:language></news:publication><news:publication_date>2026-10-29T08:43:15+01:00</news:publication_date><news:title>Idrosadenite suppurativa: le nuove linee guida per una gestione efficace della malattia</news:title></news:news></url>
<url><loc>https://www.medicinanews.it/chirurgia-cataratta-bilaterale-stesso-giorno/369013/</loc><news:news><news:publication><news:name>Medicinanews.it</news:name><news:language>it</news:language></news:publication><news:publication_date>2026-10-27T18:30:11+01:00</news:publication_date><news:title>Cataratta bilaterale operata nello stesso giorno: quando è sicura e quali precauzioni adottare</news:title></news:news></url>
<url><loc>https://www.medicinanews.it/farmaci-oncologici-beneficio-clinico-europa/369010/</loc><news:news><news:publication><news:name>Medicinanews.it</news:name><news:language>it</news:language></news:publication><news:publication_date>2026-10-27T14:27:09+01:00</news:publication_date><news:title>Farmaci oncologici innovativi: uno studio europeo rivela benefici clinici limitati per la maggior parte delle nuove terapie</news:title></news:news></url>
<url><loc>https://www.medicinanews.it/remibrutinib-sclerosi-multipla-novartis/369007/</loc><news:news><news:publication><news:name>Medicinanews.it</news:name><news:language>it</news:language></news:publication><news:publication_date>2026-10-27T13:22:20+01:00</news:publication_date><news:title>Il nuovo trattamento Novartis per la sclerosi multipla riduce le ricadute di un terzo secondo gli studi pivot</news:title></news:news></url>
</urlset>
